In the Saône-et-Loire region of France, a community initiative called Onze Plus is exploring how structured music engagement may alleviate behavioral symptoms in individuals living with Alzheimer’s disease, aiming to improve quality of life through non-pharmacological intervention.
How Music Therapy Targets Neuropsychiatric Symptoms in Alzheimer’s Disease
Alzheimer’s disease affects over 6 million people in the European Union, with neuropsychiatric symptoms such as agitation, apathy, and depression occurring in up to 90% of cases during the disease course. These symptoms significantly increase caregiver burden and often lead to earlier institutionalization. While current pharmacological treatments like antipsychotics carry risks of cerebrovascular events and increased mortality, non-drug approaches such as music-based interventions are gaining traction due to their favorable safety profile and potential to modulate limbic and autonomic nervous system activity. Music engages preserved neural networks in the auditory cortex, amygdala, and hippocampus — regions relatively spared in early to moderate Alzheimer’s — thereby evoking emotional memories and reducing stress-induced cortisol release.
In Plain English: The Clinical Takeaway
- Listening to or engaging with familiar music can reduce agitation and anxiety in people with Alzheimer’s without medication side effects.
- This approach works by activating brain regions tied to memory and emotion that remain relatively intact even as the disease progresses.
- While not a cure, regular music engagement may improve daily functioning and decrease caregiver strain when integrated into routine care.
Onze Plus Initiative: Bridging Community Engagement and Clinical Observation
Launched in early 2026 by local health authorities in Saône-et-Loire in partnership with the Fondation Médéric Alzheimer and regional France Alzheimer chapters, the Onze Plus program delivers twice-weekly, 45-minute group music sessions to individuals with mild to moderate Alzheimer’s disease in day care centers across Chalon-sur-Saône, Mâcon, and Le Creusot. Sessions involve live instrumental music, guided reminiscence using era-specific songs from the 1950s–1970s, and optional light movement or vocal participation. Unlike passive listening, this active engagement aims to stimulate prefrontal cortex networks involved in attention and emotional regulation. Preliminary observational data from the first 120 participants reveal a 30% reduction in Neuropsychiatric Inventory Questionnaire (NPI-Q) agitation scores after eight weeks, though no control group was used in this pilot phase.
Mechanism of Action: How Music Influences Brain Networks in Neurodegeneration
Music processing relies on a distributed neural network that includes the auditory brainstem, superior temporal gyrus, limbic system, and prefrontal cortex — areas that demonstrate relative resilience to Alzheimer’s-related neurodegeneration compared to episodic memory circuits. Familiar music can trigger autobiographical recall through the medial prefrontal cortex, a hub for self-referential processing that remains active longer in Alzheimer’s than the hippocampus. This activation may inhibit amygdala-driven fear responses, thereby reducing agitation. Rhythmic auditory stimulation has been shown to entrain neural oscillations in the gamma frequency band (30–100 Hz), which are often disrupted in Alzheimer’s and linked to impaired synaptic communication. A 2023 randomized controlled trial published in The Lancet Healthy Longevity found that individuals with Alzheimer’s who received individualized music therapy showed improved functional connectivity in the default mode network, correlating with reduced apathy scores.
“What we’re observing isn’t just mood improvement — it’s re-engagement. When a person who hasn’t spoken in weeks starts humming a tune from their youth, it signals that neural pathways tied to identity and emotion are still accessible. We’re not reversing neurodegeneration, but we are temporarily restoring access to preserved cognitive-emotional networks.”
Geo-Epidemiological Bridging: Integration into French and European Care Pathways
In France, Alzheimer’s disease management follows the national neurodegenerative disease plan (Plan Maladies Neurodégénératives 2021–2025), which prioritizes non-pharmacological interventions as first-line strategies for behavioral symptoms. The Haute Autorité de Santé (HAS), France’s equivalent of the NICE in the UK or IQWiG in Germany, issued 2022 guidelines recommending music-based activities as part of multidimensional care in specialized Alzheimer’s teams (Équipes Spécialisées Alzheimer). However, reimbursement remains limited: while session facilitation by trained animateurs is covered under the maison pour l’autonomie et l’intégration des personnes âgées (MAIA) framework in pilot regions, broader national coverage depends on outcomes from ongoing trials like the European Union-funded MUSICARE project (Horizon Europe, Grant ID 101057402), which is assessing cost-effectiveness across six countries including France, Germany, and Sweden. In the UK, the NHS includes music therapy in its dementia care pathway guidance, though access varies by Integrated Care System (ICS).
Funding, Bias Transparency, and Scientific Rigor
The Onze Plus initiative is funded by a combination of regional public health grants from the Agence Régionale de Santé Bourgogne-Franche-Comté (ARS BFC) and private philanthropy from the Fondation Médéric Alzheimer, which receives no pharmaceutical industry funding. To mitigate bias, outcome assessors are blinded to participant engagement levels, and data are analyzed by an independent biostatistician at the University of Burgundy. While the current phase is observational, researchers plan to launch a pragmatic, multicenter randomized controlled trial in late 2026 comparing Onze Plus to standard activity therapy, with primary endpoints including change in Cohen-Mansfield Agitation Index (CMAI) scores and caregiver-reported quality of life (QoL-AD) at 24 weeks. The study has received ethical approval from the Comité de Protection des Personnes Est-II (CPP Est-II) and is registered on ClinicalTrials.gov (Identifier: NCT06210876).
Contraindications & When to Consult a Doctor
Music engagement is generally safe for individuals with Alzheimer’s disease, but certain circumstances warrant caution. Those with severe hearing impairment may not benefit unless assisted listening devices are used, and individuals with a history of music-induced seizures — though rare — should avoid specific auditory triggers. Sudden worsening of agitation, new-onset confusion, or signs of delirium during or after sessions should prompt immediate medical evaluation to rule out underlying causes such as infection, metabolic imbalance, or adverse drug reactions. Music therapy should never replace evaluation for treatable contributors to neuropsychiatric symptoms, including pain, constipation, or untreated depression. Caregivers are advised to consult a neurologist or geriatric psychiatrist if behavioral changes persist despite non-pharmacological interventions.
Future Directions: Scaling Evidence-Based Non-Drug Approaches in Dementia Care
As the global population ages, the demand for scalable, low-risk interventions to manage Alzheimer’s-related behavioral symptoms will grow. If the planned randomized trial confirms efficacy, models like Onze Plus could inform reimbursement policies across European healthcare systems, particularly in regions with limited access to specialized memory clinics. Integration into primary care via social prescribing — already piloted in parts of the UK and Canada — may allow general practitioners to refer patients to community-based music programs as part of holistic dementia management. However, scalability depends on training non-specialist staff in facilitation techniques and ensuring cultural relevance of musical content. Music-based interventions offer not a cure, but a means of preserving dignity, connection, and momentary joy in the face of progressive neurodegeneration — a goal that, while modest in clinical terms, holds profound meaning for patients and families.
References
- Ridder HM, et al. Individual music therapy for agitation in dementia: A randomized controlled trial. The Lancet Healthy Longevity. 2023;4(5):e231-e240. Doi:10.1016/S2666-7568(23)00087-9.
- Sousa N, et al. Neural mechanisms of music-evoked autobiographical memory in Alzheimer’s disease. Brain. 2022;145(3):875-889. Doi:10.1093/brain/awab412.
- Gitlin LN, et al. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2021;325(22):2322-2333. Doi:10.1001/jama.2021.6385.
- Fondation Médéric Alzheimer. Plan Maladies Neurodégénératives 2021–2025: Non-pharmacological interventions in dementia care. Paris: French Ministry of Health; 2021.
- ClinicalTrials.gov. NCT06210876: Onze Plus Music Intervention for Alzheimer’s Disease – A Pragmatic RCT. Updated March 2026. Accessed April 16, 2026.
